news
Press release
 
July 29, 2015
CorPath® System and the Benefits of Robotic-Assisted PCI To Be Featured for the First Time in Japan

CorPath’s robotic precision and protection from occupational hazards highlighted for attending physicians at CVIT 2015

WALTHAM, MA, July 29, 2015 Corindus Vascular Robotics, Inc. [NYSE MKT: CVRS], a leading developer of precision vascular robotics, announces that Augusto D. Pichard, M.D., interventional cardiologist at Washington Hospital Center and Professor of Medicine at the George Washington University Medical Center, will discuss how robotic-assisted percutaneous coronary interventions (PCI) are applied in a modern cath lab during his presentation entitled “Robotic Coronary Angioplasty” at the 24thAnnual Meeting of the Japanese Association of Cardiovascular Intervention and Therapeutics: CVIT 2015 in Fukuoka City, Japan, on July 30.

Japan is a large market for interventional cardiology, with 250,000 PCIs performed annually across 1,000 hospitals, and has historically shown interest in robotics and radiation protection. Corindus has been invited by Takafumi Ueno, M.D., Ph.D., President of CVIT 2015, to participate and present the CorPath System in the exhibit hall for hands-on demonstrations to attendees.

"While many devices have been introduced in Japan since the first coronary intervention was performed here more than 35 years ago, we had a limited number of innovations that offered both protection for physicians and potential to improve clinical outcomes," said Dr. Ueno, Professor of Medicine, Cardiovascular Center, Kurume University Hospital. "The interventional cardiology community is open to new ideas and innovative technologies and we welcome the CorPath System to help us explore the advantages a robotic system can add to our practice."

Corindus’ CorPath System is the first FDA-cleared medical device to bring robotically assisted precision to coronary angioplasty procedures in the U.S. The CorPath System is used in cath labs throughout the U.S. for complex PCIs. In addition to allowing cardiologists to advance stents and guidewires with millimeter-by-millimeter precision using digital controls, the system enables physicians to perform procedures while seated in a lead-lined interventional cockpit protected from radiation exposure.

"CorPath is already providing robotic precision during PCI procedures while protecting physicians from the serious occupational hazards in interventional cardiology here in the United States," said David Handler, President and CEO of Corindus. "Japan is an important market for interventional cardiology and it is an honor to be invited to participate in this year’s CVIT conference."

Physicians interested in viewing the CorPath System demonstration during CVIT 2015 need to register in advance. For additional information, visit http://www2.convention.co.jp/cvit2015/en/index.html. For more information about the CorPath System, visit www.corindus.com.

About Corindus Vascular Robotics, Inc.

Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath System is the first FDA-cleared medical device to bring robotic precision to interventional procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program."

For additional information, visit www.corindus.com, and follow @CorindusInc.

Forward Looking Statements

Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future event

Examples of such statements include statements:

  • that the level of precision that can be attained using the CorPath GRX technology, combined with the potential for remote capabilities in the future, will both expand and improve how patients are treated;
  • that Corindus has entered a transformational period with a focus on expanding its reach to partner with hospitals to build robotic programs globally;
  • that the successful completion of these procedures at Fu Wai Hospital is the first step in Corindus' growth strategy within China; and that
  • the precise positioning enhancements to the CorPath platform that allows physicians to adjust guide catheters during PCI procedures may expand the use of the CorPath GRX System to more complex cases.

Media Contacts:

Corindus Vascular Robotics, Inc.

Kate Stanton
(508) 653-3335 ext. 200
kate.stanton@corindus.com

Investor Contact:

Lynn Pieper Lewis
(415) 937-5402
ir@corindus.com
 
close the window

Please complete the form below in order to download the content.








right
close the window

Please complete the form below in order to download the content.







close the window

Please fill out this brief form to subscribe to our email newsletter.





close the window

Please complete the form below and a member of our Clinical team will contact you.






close the window

Please complete the form below in order to download the content.







close the window